Your browser doesn't support javascript.
loading
IMMUNOTAR - Integrative prioritization of cell surface targets for cancer immunotherapy.
Shraim, Rawan; Mooney, Brian; Conkrite, Karina L; Weiner, Amber K; Morin, Gregg B; Sorensen, Poul H; Maris, John M; Diskin, Sharon J; Sacan, Ahmet.
Affiliation
  • Shraim R; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
  • Mooney B; School of Biomedical Engineering, Science and Health System, Drexel University, Philadelphia, PA 19104, USA.
  • Conkrite KL; Department of Molecular Oncology, BC Cancer Research Institute, Vancouver, BC, Canada.
  • Weiner AK; Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada.
  • Morin GB; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
  • Sorensen PH; Division of Oncology and Center for Childhood Cancer Research, Children's Hospital of Philadelphia, Philadelphia, PA, 19104, USA.
  • Maris JM; Canada's Michael Smith Genome Sciences Centre, BC Cancer Research Institute, Vancouver, BC, Canada.
  • Diskin SJ; Department of Medical Genetics, University of British Columbia, Vancouver, BC, Canada.
  • Sacan A; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, BC, Canada.
bioRxiv ; 2024 Jun 06.
Article de En | MEDLINE | ID: mdl-38895237
ABSTRACT
Cancer remains a leading cause of mortality globally. Recent improvements in survival have been facilitated by the development of less toxic immunotherapies; however, identifying targets for immunotherapies remains a challenge in the field. To address this challenge, we developed IMMUNOTAR, a computational tool that systematically prioritizes and identifies candidate immunotherapeutic targets. IMMUNOTAR integrates user-provided RNA-sequencing or proteomics data with quantitative features extracted from publicly available databases based on predefined optimal immunotherapeutic target criteria and quantitatively prioritizes potential surface protein targets. We demonstrate the utility and flexibility of IMMUNOTAR using three distinct datasets, validating its effectiveness in identifying both known and new potential immunotherapeutic targets within the analyzed cancer phenotypes. Overall, IMMUNOTAR enables the compilation of data from multiple sources into a unified platform, allowing users to simultaneously evaluate surface proteins across diverse criteria. By streamlining target identification, IMMUNOTAR empowers researchers to efficiently allocate resources and accelerate immunotherapy development.
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: BioRxiv Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Langue: En Journal: BioRxiv Année: 2024 Type de document: Article Pays d'affiliation: États-Unis d'Amérique
...